Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263088 | 0.73 | MEN1 (0.37) | TSHR | |
| SCHEMBL6968100 | 0.68 | — | — | |
| SCHEMBL17408807 | 0.68 | — | — | |
| SCHEMBL2851785 | 0.68 | ALDH1A1 (0.41) | — | |
| SCHEMBL6967195 | 0.66 | ALDH1A1 (0.43) | — | |
| SCHEMBL2848935 | 0.66 | ALDH1A1 (0.40) | TSHR | |
| SCHEMBL5956026 | 0.65 | — | — | |
| SCHEMBL5956305 | 0.65 | — | — | |
| SCHEMBL5956012 | 0.65 | — | — | |
| SCHEMBL10746176 | 0.64 | MAPT (0.48) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630851-B2 | Polynucleotide modification methods | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-19 | — | — | US | claimed |
| US-12084715-B1 | Methods and systems for reducing artifactual antisense products | 10X GENOMICS, INC. (US) | 2024-09-10 | — | — | US | claimed |
| US-20220186274-A1 | POLYNUCLEOTIDE MODIFICATION METHODS | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2022-06-16 | — | — | US | claimed |
| US-11186857-B2 | Polynucleotide modification methods | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2021-11-30 | — | — | US | claimed |
| US-20200131549-A1 | POLYNUCLEOTIDE MODIFICATION METHODS | OXFORD NANOPORE TECHNOLOGIES LTD. (GB) | 2020-04-30 | — | — | US | claimed |
| EP-3033435-B1 | METHOD FOR FRAGMENTING NUCLEIC ACID BY MEANS OF TRANSPOSASE | OXFORD NANOPORE TECH LTD (GB) | 2019-07-24 | — | — | EP | claimed |
| EP-3033435-A1 | METHOD | Oxford Nanopore Technologies Limited (GB) | 2016-06-22 | — | — | EP | claimed |
| WO-2015022544-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) | 2015-02-19 | — | — | WO | claimed |
| US-7811753-B2 | Methods for repairing degraded DNA | IBIS BIOSCIENCES, INC. (US) | 2010-10-12 | — | — | US | claimed |
| US-7531306-B2 | Nucleic acid hybridization methods | GENEOHM SCIENCES, INC. (US) | 2009-05-12 | — | — | US | claimed |
| EP-1689879-A4 | NUCLEIC ACID HYBRIDIZATION METHODS | GENEOHM SCIENCES INC (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1689879-A2 | NUCLEIC ACID HYBRIDIZATION METHODS | Geneohm Sciences, Inc. (US) | 2006-08-16 | — | — | EP | claimed |
| WO-2006019784-A2 | METHODS FOR REPAIRING DEGRADED DNA | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20060014154-A1 | Methods for repairing degraded DNA | IBIS BIOSCIENCES, INC. | 2006-01-19 | — | — | US | claimed |
| US-20050176035-A1 | Destabilization of hybridization via DNA N-glycosylase/uridine nucleosidase, insertion of probe; kits | GENEOHM SCIENCE, INC. | 2005-08-11 | — | — | US | claimed |
| WO-2005049848-A2 | NUCLEIC ACID HYBRIDIZATION METHODS | GENEOHM SCIENCES, INC. (US) | 2005-06-02 | — | — | WO | claimed |
| US-12630851-B2 | Polynucleotide modification methods | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-05-19 | — | — | US | disclosed |
| US-20260015392-A1 | MUTANT CSGG PORES | OXFORD NANOPORE TECHNOLOGIES PLC (BE) | 2026-01-15 | — | — | US | disclosed |
| US-20030104459-A1 | Multiplex PCR | AFFYMETRIX, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003044177-A2 | MULTIPLEX PCR | PARALLELE BIOSCIENCE, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630851-B2 | Polynucleotide modification methods | PNP, NT5C3B, UNG | TSHR 2677/4885 |
| US-20260015392-A1 | MUTANT CSGG PORES | NPPA, AFG3L2, SCAMP3 | TSHR 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.